Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience

Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma (RCC), next to vascular endothelial growth factor receptor 2, KIT, FLT3 and RET. Chronic treatment with vascular endothelial growth fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Osanto, Susanne, van der Hulle, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896860/
https://www.ncbi.nlm.nih.gov/pubmed/29662541
http://dx.doi.org/10.1177/1756287217748867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896860/
https://www.ncbi.nlm.nih.gov/pubmed/29662541
http://dx.doi.org/10.1177/1756287217748867

Ejemplares similares